APA

Harvey V. J., Slevin M. L., Woollard R. C., Johnston A., Barnett M. J., Wrigley P. F. & Turner P. (19840928). The bioavailability of oral intermediate-dose methotrexate. Effect of dose subdivision, formulation, and timing in the chemotherapy cycle. : Cancer chemotherapy and pharmacology.

Chicago

Harvey V J, Slevin M L, Woollard R C, Johnston A, Barnett M J, Wrigley P F and Turner P. 19840928. The bioavailability of oral intermediate-dose methotrexate. Effect of dose subdivision, formulation, and timing in the chemotherapy cycle. : Cancer chemotherapy and pharmacology.

Harvard

Harvey V. J., Slevin M. L., Woollard R. C., Johnston A., Barnett M. J., Wrigley P. F. and Turner P. (19840928). The bioavailability of oral intermediate-dose methotrexate. Effect of dose subdivision, formulation, and timing in the chemotherapy cycle. : Cancer chemotherapy and pharmacology.

MLA

Harvey V J, Slevin M L, Woollard R C, Johnston A, Barnett M J, Wrigley P F and Turner P. The bioavailability of oral intermediate-dose methotrexate. Effect of dose subdivision, formulation, and timing in the chemotherapy cycle. : Cancer chemotherapy and pharmacology. 19840928.